Rivastigmine

Rivastigmine
Clinical data
Trade names	Exelon, Prometax, others
AHFS/Drugs.com	Monograph
MedlinePlus	a602009
License data	EU EMA: by INN; US DailyMed: Rivastigmine;
Pregnancy; category	AU: B2;
Routes of; administration	By mouth, transdermal patch
ATC code	N06DA03 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	60 to 72%
Protein binding	40%
Metabolism	Liver, via pseudocholinesterase
Elimination half-life	1.5 hours
Excretion	97% in urine
Identifiers
	IUPAC name (S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate;
CAS Number	123441-03-2 ;
PubChem CID	77991;
IUPHAR/BPS	6602;
DrugBank	DB00989 ;
ChemSpider	70377 ;
UNII	PKI06M3IW0;
KEGG	D03822 ;
ChEBI	CHEBI:8874 ;
ChEMBL	ChEMBL636 ;
CompTox Dashboard (EPA)	DTXSID7023564 ;
ECHA InfoCard	100.120.679
Chemical and physical data
Formula	C14H22N2O2
Molar mass	250.342 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Oc1cc(ccc1)[C@@H](N(C)C)C)N(CC)C;
	InChI InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1 ; Key:XSVMFMHYUFZWBK-NSHDSACASA-N ;
	(what is this?) (verify)

Rivastigmine (sold under the trade name Exelon among others) is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions.

It was patented in 1985 and came into medical use in 1997.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.